LifeMD Expands Pharmacy Services with Non-Sterile Compounding to Deliver Personalized, Cost-Efficient Therapies at Scale
Rhea-AI Summary
LifeMD (Nasdaq: LFMD) has expanded its affiliated pharmacy services to include non-sterile compounding capabilities for oral and topical medications. This enhancement follows the August 2024 launch of their commercial pharmacy, which can process up to 5,000 prescriptions daily.
The expanded facility will enable LifeMD to formulate customized medications, including allergen-free and combination products not commercially available. Operating under FDA's 503A designation, the pharmacy is currently licensed in 13 states and aims to secure licenses across all 50 states within 12 months.
This strategic expansion supports LifeMD's core service areas in men's and women's health and dermatology while reducing third-party provider dependence and improving operational efficiency.
Positive
- Enhanced ability to provide personalized medications through non-sterile compounding
- Capacity to process up to 5,000 prescriptions per day
- Reduced dependence on third-party providers, potentially improving margins
- Expected expansion from 13 to 50 state licenses within 12 months
Negative
- None.
News Market Reaction
On the day this news was published, LFMD gained 5.76%, reflecting a notable positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $17M to the company's valuation, bringing the market cap to $311M at that time.
Data tracked by StockTitan Argus on the day of publication.
Enhanced Affiliated Pharmacy Capabilities Support Specialized Therapies, Seamless Patient Experience, and Margin Expansion
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care services, today announced the expansion of its state-of-the-art affiliated pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications. This milestone extends LifeMD’s pharmacy growth strategy by enabling its vertically integrated platform to deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing reliance on third-party providers.
LifeMD’s commercial pharmacy, launched in August 2024 with capacity to process up to 5,000 prescriptions per day, can now formulate customized medications, including allergen-free and combination products not commercially available. These capabilities align with LifeMD’s core service areas in men’s and women’s health, dermatology, and beyond. The addition strengthens the Company’s ability to support specialized therapies while driving operational savings, shortening fulfillment times, and improving patient convenience.
“Every action we take is focused on strengthening LifeMD’s ability to deliver higher-quality, more accessible care to our patients,” said Justin Schreiber, Chairman and CEO of LifeMD. “By expanding our pharmacy with non-sterile compounding, we are not just adding capabilities, we’re building toward a future where every patient’s care is seamless, personalized, and accessible. This advancement complements our core service areas and brings us closer to delivering an unmatched healthcare experience, where convenience, continuity, and innovation come together to provide the kind of care that people want and deserve.”
LifeMD’s compounding pharmacy operates under the U.S. Food and Drug Administration’s 503A designation to directly meet specific patient needs with custom-formulated products. The Company is committed to adhering to strict quality and safety standards set by both federal and state regulations. LifeMD’s pharmacy is currently licensed in 13 states, with expectations to attain licenses in all 50 states within the next 12 months.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated compounding pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Cautionary Note Regarding Forward Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Investor Contact:
Marc Benathen, Chief Financial Officer
marc@lifemd.com
Media Contact:
Jessica Friedeman, Chief Marketing and Product Officer
press@lifemd.com
FAQ
What new pharmacy capabilities did LifeMD (LFMD) announce in September 2025?
How many prescriptions can LifeMD's commercial pharmacy process daily?
In how many states is LifeMD's pharmacy currently licensed?
What type of FDA designation does LifeMD's compounding pharmacy operate under?
What are the main therapeutic areas served by LifeMD's expanded pharmacy services?
